menu search

Aligos therapeutics to host kol event to discuss alg-000184 phase 1, aasld late breaker data

November 16 Event to feature KOL perspective on Emerging HBV Therapies SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) — Aligos Therapeu...

November 3, 2023, 8:30 pm

Wave life sciences third quarter 2023 financial results scheduled for november 9, 2023

CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delive...

November 3, 2023, 8:05 pm

New preliminary clinical data on potential of opus aav-based gene therapy for rare inherited retinal disease to be presented at the american academy of ophthalmology annual conference 2023

Data to be presented as part of gene augmentation therapy presentation RALEIGH, N.C., Nov. 03, 2023 (GLOBE NEWSWIRE) — Opus Genetics, a patient-focu...

November 3, 2023, 7:43 pm

Taysha gene therapies: tsha-102's potential is a 'buy'

Taysha Gene Therapies is a biotech stock focused on developing gene therapies for monogenic CNS diseases...

November 3, 2023, 7:41 pm

Quoin pharmaceuticals announces third quarter 2023 financial results and corporate update conference call to be held on thursday november 9th at 8:30 am et

ASHBURN, Va., Nov. 03, 2023 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specia...

November 3, 2023, 12:41 pm

Gilead to present late breaking data and real world evidence highlighting key hepatitis indications at the liver meeting® 2023

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new viral hepatitis data at the America...

November 3, 2023, 11:00 am

Quoin pharmaceuticals announces third quarter 2023 financial results and corporate update conference call to be held on thursday november 9th at 8:30 am et

ASHBURN, Va., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage special...

November 3, 2023, 8:41 am

Astria therapeutics to present new star-0215 data at the 2023 american college of allergy, asthma, and immunology annual scientific meeting

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allerg...

November 3, 2023, 8:10 am

Acadia pharmaceuticals inc. (acad) q3 2023 earnings call transcript

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q3 2023 Earnings Conference Call November 2, 2023 5:00 PM ET Company Participants Jessica Tieszen - Associa...

November 3, 2023, 3:54 am

Lexeo therapeutics announces pricing of initial public offering

NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) — Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to transform...

November 3, 2023, 1:51 am

Cidara therapeutics provides corporate update and reports third quarter 2023 financial results

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company focused on developing targeted therapi...

November 2, 2023, 8:15 pm

The north america rare disease summit focused on the need for centralized data to improve the lives of 30 million people living with rare conditions

Stakeholders debate at the North America Rare Disease Summit on the challenges regarding treatment approvals, the importance of a deep proactive regis...

November 2, 2023, 7:51 pm

Genfit to present update on scientific and corporate progress at the liver meeting® 2023

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 2 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage bio...

November 2, 2023, 5:10 pm

Inari medical to present at upcoming investor conferences

IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat a...

November 2, 2023, 4:01 pm

Corvus pharmaceuticals announces publication of preclinical data demonstrating potential of itk inhibition with soquelitinib as a novel approach to t cell-mediated inflammatory and immune diseases

Data demonstrated soquelitinib was active in six inflammatory/immune disease models and provides rationale for development in a range of additional Th...

November 1, 2023, 11:31 pm

Biocardia to host q3 2023 corporate update and financial results conference call on november 8, 2023

SUNNYVALE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the t...

November 1, 2023, 9:04 pm

Biocardia to host q3 2023 corporate update and financial results conference call on november 8, 2023

SUNNYVALE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the tr...

November 1, 2023, 5:04 pm

Masonic cancer center, university of minnesota to present data in poster presentation human data readout for phase 1 study to evaluate hcw9218 in solid tumors at sitc 38th annual meeting

HCW9218 is the lead product candidate of HCW Biologics Inc. MIRAMAR, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or...

November 1, 2023, 11:30 am

Springworks therapeutics announces presentation of additional data from phase 3 defi trial of nirogacestat in adults with desmoid tumors at the 2023 ctos annual meeting

– Nirogacestat Treatment Demonstrated Rapid and Sustained Improvements in Functional Status Compared to Placebo Across Multiple Assessment Tools –...

November 1, 2023, 10:30 am

Tearsolutions, inc. appoints robert dempsey to its board of directors

Dempsey brings worldwide Ophthalmology leadership experience in driving successful drug development CHARLOTTESVILLE, Va., Nov. 01, 2023 (GLOBE NEWSWIR...

November 1, 2023, 10:00 am


Search within

Pages Search Results: